148 related articles for article (PubMed ID: 25715244)
1. Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion based patient experience.
Tachdjian R; Banerji A; Guyer A; Morphew T
Allergy Asthma Proc; 2015; 36(2):151-9. PubMed ID: 25715244
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
4. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
5. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
6. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E; Horn P; Craig TJ
Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
[TBL] [Abstract][Full Text] [Related]
8. Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys.
Reshef A; Prematta MJ; Craig TJ
Allergy Asthma Proc; 2013; 34(3):261-6. PubMed ID: 23676575
[TBL] [Abstract][Full Text] [Related]
9. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
[TBL] [Abstract][Full Text] [Related]
10. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks.
Prematta MJ; Bewtra AK; Levy RJ; Wasserman RL; Jacobson KW; Machnig T; Craig TJ
Adv Ther; 2012 Oct; 29(10):913-22. PubMed ID: 23054691
[TBL] [Abstract][Full Text] [Related]
11. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
[TBL] [Abstract][Full Text] [Related]
12. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden.
Nordenfelt P; Dawson S; Wahlgren CF; Lindfors A; Mallbris L; Björkander J
Allergy Asthma Proc; 2014; 35(2):185-90. PubMed ID: 24411585
[TBL] [Abstract][Full Text] [Related]
13. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
14. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
15. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe.
Caballero T; Aygören-Pürsün E; Bygum A; Beusterien K; Hautamaki E; Sisic Z; Wait S; Boysen HB
Allergy Asthma Proc; 2014; 35(1):47-53. PubMed ID: 24268449
[TBL] [Abstract][Full Text] [Related]
16. Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial.
Javaud N; Fain O; Durand-Zaleski I; Launay D; Bouillet L; Gompel A; Sobel A; Woimant M; Rabetrano H; Petrovic T; Lapostolle F; Boccon-Gibod I; Reuter PG; Bertrand P; Coppere B; Floccard B; Kanny G; Martin L; Vicaut E; Adnet F
Trials; 2016 Apr; 17(1):225. PubMed ID: 27140403
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
19. Facilitating home-based treatment of hereditary angioedema.
Bernstein JA; Riedl M; Zacek L; Shapiro RS
Allergy Asthma Proc; 2015; 36(2):92-9. PubMed ID: 25551795
[TBL] [Abstract][Full Text] [Related]
20. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
